期刊
JOURNAL OF HEMATOLOGY & ONCOLOGY
卷 9, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s13045-016-0354-2
关键词
-
资金
- Leukemia and Lymphoma Research Society of Canada (LLSC)
- Cancer Research Society (CRS)
- Shanghai Science and Technology International Collaboration Project [15410710300]
The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据